vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.
READING INTERNATIONAL INC is the larger business by last-quarter revenue ($50.3M vs $27.6M, roughly 1.8× Beta Bionics, Inc.). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -79.3%, a 74.2% gap on every dollar of revenue. On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs -14.2%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
BBNX vs RDI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $50.3M |
| Net Profit | $-21.9M | $-2.6M |
| Gross Margin | 59.5% | — |
| Operating Margin | -47.4% | -1.9% |
| Net Margin | -79.3% | -5.1% |
| Revenue YoY | 56.6% | -14.2% |
| Net Profit YoY | 23.6% | -14.5% |
| EPS (diluted) | $-0.49 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | $50.3M | ||
| Q3 25 | $27.3M | $52.2M | ||
| Q2 25 | $23.2M | $60.4M | ||
| Q1 25 | $17.6M | $40.2M | ||
| Q4 24 | — | $58.6M | ||
| Q3 24 | — | $60.1M | ||
| Q2 24 | — | $46.8M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | $-2.6M | ||
| Q3 25 | $-14.2M | $-4.2M | ||
| Q2 25 | $-16.9M | $-2.7M | ||
| Q1 25 | $-28.7M | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | — | $-7.0M | ||
| Q2 24 | — | $-12.8M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | — | ||
| Q3 25 | 55.5% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 50.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | -1.9% | ||
| Q3 25 | -62.5% | -0.6% | ||
| Q2 25 | -85.5% | 4.8% | ||
| Q1 25 | -105.7% | -17.2% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | -0.6% | ||
| Q2 24 | — | -16.4% |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | -5.1% | ||
| Q3 25 | -52.1% | -8.0% | ||
| Q2 25 | -72.6% | -4.4% | ||
| Q1 25 | -162.5% | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | — | -11.7% | ||
| Q2 24 | — | -27.4% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | $-0.11 | ||
| Q3 25 | $-0.33 | $-0.18 | ||
| Q2 25 | $-0.39 | $-0.12 | ||
| Q1 25 | $-0.93 | $-0.21 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $-0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $10.5M |
| Total DebtLower is stronger | — | $185.1M |
| Stockholders' EquityBook value | $271.2M | $-18.2M |
| Total Assets | $304.4M | $434.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | $10.5M | ||
| Q3 25 | $228.7M | $8.1M | ||
| Q2 25 | $249.7M | $9.1M | ||
| Q1 25 | $231.5M | $5.9M | ||
| Q4 24 | — | $12.4M | ||
| Q3 24 | — | $10.1M | ||
| Q2 24 | — | $9.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | $-18.2M | ||
| Q3 25 | $294.8M | $-12.1M | ||
| Q2 25 | $301.6M | $-7.7M | ||
| Q1 25 | $313.8M | $-8.1M | ||
| Q4 24 | — | $-4.4M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $6.5M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | $434.9M | ||
| Q3 25 | $330.0M | $435.2M | ||
| Q2 25 | $330.0M | $438.1M | ||
| Q1 25 | $338.0M | $441.0M | ||
| Q4 24 | — | $471.0M | ||
| Q3 24 | — | $495.7M | ||
| Q2 24 | — | $494.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $4.3M |
| Free Cash FlowOCF − Capex | — | $4.1M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $4.3M | ||
| Q3 25 | $-8.7M | $295.0K | ||
| Q2 25 | $-13.6M | $1.6M | ||
| Q1 25 | $-20.0M | $-7.7M | ||
| Q4 24 | — | $8.0M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $-10.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | $4.1M | ||
| Q3 25 | $-10.0M | $-246.0K | ||
| Q2 25 | $-15.4M | $1.2M | ||
| Q1 25 | $-20.3M | $-8.0M | ||
| Q4 24 | — | $7.0M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-10.6M |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | 8.2% | ||
| Q3 25 | -36.7% | -0.5% | ||
| Q2 25 | -66.2% | 1.9% | ||
| Q1 25 | -115.1% | -19.8% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | — | -1.8% | ||
| Q2 24 | — | -22.7% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 0.3% | ||
| Q3 25 | 4.7% | 1.0% | ||
| Q2 25 | 7.7% | 0.6% | ||
| Q1 25 | 1.9% | 0.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBNX
Segment breakdown not available.
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
